Study Reveals Treatment Strategy for Triple-Negative Breast Cancer
Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.
Mateusz Opyrchal, MD, PhD, of Roswell Park Cancer Institute in Buffalo, talks about a novel interaction between AURKA and the MAPK pathway in wild-type BRAF breast cancer cells and the cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen-positive and triple-negative breast cancer cells.
Dr. Opyrchal gave a presentation at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
